Related Experiment Video
Updated: Jun 29, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Atriplatrade mark - HIV therapy in one pill
Boris Julg1, Johannes R Bogner
1Medizinische Poliklinik, Department of Infectious Diseases, University of Munich Medical School Downtown Campus, Germany.
Therapeutics and Clinical Risk Management
|October 2, 2008
Summary
Atripla, a once-daily HIV-1 treatment combining efavirenz, emtricitabine, and tenofovir disoproxil fumarate, offers a potent and well-tolerated option for adults. Its efficacy and safety are reviewed against other initial antiretroviral therapies.
Area of Science:
- Infectious Diseases
- Pharmacology
- Virology
Background:
- Atripla, approved in 2006 by the FDA, is the first single-pill, once-daily regimen for HIV-1 treatment in adults.
- It combines efavirenz (an NNRTI) with emtricitabine and tenofovir disoproxil fumarate (NRTIs).
- These components were chosen for their established potency, tolerability, and safety profiles in prior use.
Purpose of the Study:
- To review the efficacy and safety data of the individual components of Atripla: efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
- To compare these antiretroviral drugs with other agents recommended for initial therapy in treatment-naive patients.
Main Methods:
- Review of existing efficacy and safety data for efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
- Comparative analysis of these drugs against other first-line antiretroviral therapies.
Main Results:
- Efavirenz, emtricitabine, and tenofovir disoproxil fumarate are potent antiretroviral agents with favorable tolerability and safety profiles.
- The combination offers a convenient once-daily dosing regimen for HIV-1 management.
Conclusions:
- Atripla provides a valuable and effective once-daily treatment option for HIV-1 infection in adults.
- The individual components are well-established and recommended for initial antiretroviral therapy.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...